Proton MR Spectroscopy and Imaging of a Galactosemic Patient before and after Dietary Treatment

References

1. ↵
   Moolenaar SH, van der Knaap MS, Engelke UFH, et al. In vivo and in vitro NMR spectroscopy reveal a putative novel inborn error involving polyol metabolism. NMR Biomed 2001;14:167–76

   CrossRefPubMedWeb of Science
2. ↵
   Berry GT, Hunter JV, Wang Z, et al. In vivo evidence of brain galactitol accumulation in an infant with galactosemia and encephalopathy. J Pediatr 2001;138:260–62

   CrossRefPubMedWeb of Science
3. ↵
   Stambolian D. Galactose and cataract. Surv Ophthalmol 1988;32:333–49

   CrossRefPubMedWeb of Science
4. ↵
   Leslie ND. Insights into the pathogenesis of galactosemia. Annu Rev Nutr 2003;23:59–80

   CrossRefPubMedWeb of Science
5. ↵
   Elsas LJ 2nd, Lai K. The molecular biology of galactosemia. Genet Med 1998;1:40–48

   CrossRefPubMedWeb of Science
6. ↵
   Gitzelmann R, Steinmann B. Galactosemia: how does long-term treatment change the outcome? Enzyme 1984;32:37–46

   PubMedWeb of Science
7. ↵
   Palmieri M, Mazur A, Berry GT, et al. Urine and plasma galactitol in patients with galactose-1-phosphate uridyltransferase deficiency galactosemia. Metabolism 1999;48:1294–1302

   CrossRefPubMedWeb of Science
8. ↵
   Nelson MD, Wolff JA, Cross CA, et al. Galactosemia: evaluation with MR imaging. Radiology 1992;184:255–61

   PubMedWeb of Science
9. ↵
   Wang ZJ, Berry GT, Dreha SF, et al. Proton magnetic resonance spectroscopy of brain metabolites in galactosemia. Ann Neurol 2001;50:266–69

   CrossRefPubMedWeb of Science
10. ↵
    Wehrli SL, Berry GT, Palmieri M, et al. Urinary galactonate in patients with galactosemia: quantitation by NMR spectroscopy. Pediatric Res 1997;42:855–61

    PubMedWeb of Science
11. ↵
    van der Knaap MS, Wevers RA, Struys EA, et al. Leukoencephalopathy associated with a disturbance in the metabolism of polyols. Ann Neurol 1999;46:925–28

    CrossRefPubMedWeb of Science